Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
BLONDER TONGUE LABORATORIES INC (BDR) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/01/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "BLONDER TONGUE ANNOUNCES DEATH OF SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER ERIC SKOLNIK Old Bridge, N.J. – February 23, 2023 – It is with great sadness that Blonder Tongue Laboratories, Inc. Board of Directors announce the death of Senior Vice President and Chief Financial Officer, Eric S. Skolnik. He was 58. “Eric was a most trusted friend and business colleague,” says Bob Palle, incoming CEO of Blonder Tongue. “Eric cared for each and every person that makes up the Blonder Tongue family. Eric’ s tireless work ethic and caring nature would lighten your workload and brighten your outlook following any interaction with him. We loved Eric. Our hearts are with his family at this difficult time. May he rest in peace.” Eric joined Blonder Tongue as the Corporate Controller starting in ..."
02/13/2023 8-K Quarterly results
01/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Blonder Tongue Announces Departure of CEO Reappoints Robert J Palle to Chief Executive Officer and President OLD BRIDGE, New Jersey—January 23, 2023—Blonder Tongue Laboratories, Inc. announced that Edward R. “Ted” Grauch has resigned as Chief Executive Officer and President effective March 18, 2023. Mr. Grauch has held these roles since January 1, 2020, and will remain in these roles until March 18, 2023. The Company’ s Board of Directors has reappointed Robert J “Bob” Palle to serve as Chief Executive Officer and President of the Company, concurrent with Ted’ s departure. Bob has been a Director of Blonder Tongue Laboratories since September 1993. He served as our President from May 2003 until May 2019, our Chief Executive Officer from May 2015 until December 31, 2019 and our Managing Di..."
01/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Deferred Compensation Agreement, by and between Blonder Tongue Laboratories, Inc. and Edward R. Grauch"
11/04/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
10/31/2022 8-K Quarterly results
07/06/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
06/15/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
06/01/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/06/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/08/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "NINTH AMENDMENT TO LOAN AGREEMENT, DATED APRIL 5, 2022."
03/31/2022 8-K Quarterly results
Docs: "Blonder Tongue Reports Year End and Fourth Quarter 2021 Results OLD BRIDGE, NJ / March 31, 2022 / Blonder Tongue Laboratories, Inc. announced its sales and results for the fourth quarter and year ended December 31, 2021. Commenting on the Company’ s year end and fourth quarter results, Chief Executive Officer Ted Grauch noted, “Although the Company was able to realize positive net earnings for the full year of 2021, the global semiconductor supply chain bottlenecks and supply uncertainties had a significant negative impact on our fourth quarter financial performance, and a number of those supply chain issues have continued into this year. We have been managing through this challenging environment with a combination of product price increases to compensate for raw material premiums, coupled..."
03/14/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Blonder Tongue Announces Review of Strategic Alternatives OLD BRIDGE, NJ / March 14, 2022 / Blonder Tongue Laboratories, Inc. announced today that its Board of Directors has authorized a review of strategic alternatives for the Company aimed at enhancing stockholder value. Emerging Growth Equities, Ltd. has been engaged to serve as the exclusive financial advisor to the Board of Directors. The Company does not intend to make any further statements regarding the process of reviewing strategic alternatives unless and until a definitive agreement has been reached or until the process has otherwise ended, unless required by applicable law. No assurance can be given as to whether, when or on what terms any possible transaction might occur. About Blonder Tongue"
03/04/2022 8-K Quarterly results
02/15/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "SEVENTH AMENDMENT TO LOAN AGREEMENT, DATED FEBRUARY 11, 2022"
02/04/2022 8-K Quarterly results
01/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/17/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "SIXTH AMENDMENT TO LOAN AGREEMENT, DATED DECEMBER 16, 2021"
12/14/2021 8-K Quarterly results
12/10/2021 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ...
Docs: "Blonder Tongue Announces Receipt of Notice of Delisting from NYSE American"
11/15/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "OPINION OF STRADLEY RONON STEVENS & YOUNG, LLP",
"STOCK PURCHASE AGREEMENT"
10/22/2021 8-K Quarterly results
Docs: "Blonder Tongue Announces Third Quarter and Nine- Month 2021 Results OLD BRIDGE, NJ / October 22, 2021 / Blonder Tongue Laboratories, Inc. announced its sales and results for the third quarter and nine months ended September 30, 2021. Blonder Tongue Laboratories, Inc. net sales increased $1,000 or 0.02% to $4,172,000 for the third quarter of 2021 from $4,171,000 for the comparable period in 2020. Net loss for the three months ended September 30, 2021, was $ or $ per diluted share, compared to a net loss of $ or $ per diluted share for the comparable period in 2020. Commenting on the third quarter results, Ted Grauch, Blonder Tongue Laboratories’ President and CEO noted, “The Company made strong progress in the third quarter on several fronts. We’ ve continued to grow sales of our high techn..."
08/30/2021 8-K Quarterly results
08/23/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "OPINION OF STRADLEY RONON STEVENS & YOUNG, LLP",
"STOCK PURCHASE AGREEMENT"
08/16/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "BLONDER TONGUE LABORATORIES, INC. $400,000 Common Stock Sales Agreement",
"OPINION OF STRADLEY RONON STEVENS & YOUNG, LLP"
08/12/2021 8-K Quarterly results
Docs: "Blonder Tongue Announces Second Quarter and Six Months 2021 Results OLD BRIDGE, NJ / August 12, 2021 / Blonder Tongue Laboratories, Inc. announced its sales and results for the second quarter and six months ended June 30, 2021. Blonder Tongue Laboratories, Inc. net sales increased $507,000 or 13.2% to $4,338,000 for the second quarter of 2021 from $3,831,000 for the comparable period in 2020. Net income for the three months ended June 30, 2021, was $1,626,000 or $0.11 per diluted share, compared to a net loss of $ or $ per diluted share for the comparable period in 2020. Commenting on the second quarter results, Ted Grauch, Blonder Tongue Laboratories’ President and CEO noted, “In Q2 the Company saw several elements of our long-term strategy begin to come together yielding a positive first..."
08/02/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy